Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lerociclib - G1 Therapeutics/Genor Biopharma

Next Previous
Drug Profile

Lerociclib - G1 Therapeutics/Genor Biopharma

Alternative Names: G1T-38; GB-491

Latest Information Update: 09 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator G1 Therapeutics
  • Developer EQRx; G1 Therapeutics; Genor Biopharma
  • Class Amines; Antineoplastics; Aza compounds; Heterocyclic compounds with 4 or more rings; Ketones; Piperazines; Pyridines; Small molecules; Spiro compounds
  • Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered HER2 negative breast cancer
  • Phase I/II Non-small cell lung cancer
  • No development reported Cancer

Most Recent Events

  • 06 Jun 2025 Lerociclib is no longer licensed to Deimos Biosciences in worldwide
  • 29 May 2025 Registered for HER2-negative-breast-cancer (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in China (PO) - First global approval (9444189)
  • 29 May 2025 Registered for HER2-negative-breast-cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (PO) - First global approval (9444189)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top